EBSA Conference 2025 and Preconference courses - Program
EBSA Conference 2025 and Preconference courses
Schedule of EBSA Conference 2025 and Preconference courses
-
From 8:00 to 16:00
14:00-18:30 - International Biosecurity Symposium
Organised by the Dutch Biosecurity Office
Free attendance, check the box during the registration for the EBSA conference or the preconference courses.
-
From 9:00 to 9:40
Session 1 One Health and Biosafety - Biosurveillance in a one health context - Marion Koopmans
Marion Koopmans, Head of the Erasmus MC department of Viroscience, Erasmus MC, The Netherlands
Recent examples of epidemics and pandemics have shown the importance of early detection as a key pillar of outbreak preparedness. As many emerging disease outbreaks are initiated by a spillover of animal viruses, there is increasing interest in surveying animal populations and environments in which humans and animals interact, often combined with the use of data analytics to identify hotspots where sampling can be targeted. With increasing recognition of microbial and viral diversity in animal hosts, this is often combined with metagenomics, a catch-all technique in which characterization of all DNA and RNA in a sample is done, in theory capturing any virus that is present in sufficient quantities. This has led to the discovery of numerous new viruses and a fundamental shift in our understanding of viruses. Viruses are omnipresent and recognizing which of the genomes is associated with potential human health risk is a critical step. This presentation will discuss biosurveillance and examples of its utility, as well as challenges.
-
From 9:40 to 10:00
Session 1 One Health and Biosafety - ONE HEALTH, ONE SAFETY, ONE EUROPE! Integrating Biosecurity and One Health in Europe’s approach to Food Safety and Food Systems. - Carlos Gonçalo das Neves
Carlos Gonçalo das Neves, Chief Scientist, EFC
In today’s shifting geopolitical landscape, Europe faces growing biosecurity challenges that require an integrated One Health approach—linking human, animal, and ecosystem health. Food safety, as a critical biosecurity concern, must be addressed holistically to mitigate a broad range of risks.Among others, geopolitical instability, conflicts, and supply chain disruptions heighten the spread of pathogens and bioterrorism risks; climate change alters disease patterns, increasing foodborne and zoonotic threats; and new food productions systems may amplify pathogen spillover, increase biodiversity loss or have adverse climate impacts. The One Health framework is essential for managing these risks by ensuring stronger links between veterinary health, public health, and environmental monitoring. -
From 10:10 to 10:30
Session 1 One Health and Biosafety - Pioneering the Future: Advances, Applications, and Safety of Genetically Modified Phages - Pascale Van Rooij
Pascale Van Rooij, Biosafety specialist, Perseus a 3Bio company, Belgium
Bacteriophages, the natural predators of bacteria, are emerging as valuable tools across various sectors, including medicine, diagnostics, food safety, and agriculture. They offer targeted strategies to combat bacterial infections and multidrug antibiotic resistance. Genetic modification can enhance their efficacy and safety for specific applications. However, public opinion on bacteriophage therapy is mixed, with some viewing it as a promising alternative to antibiotics, while others express safety and regulatory concerns.In this presentation, we will share the results of a study commissioned by the Netherlands Committee for Genetic Modification (COGEM) on the current applications of wild-type phages and advancements in the genetic modification of phages. Our findings are based on literature reviews, patent screenings, and expert consultations.Genetically modified phages are primarily in the development phase, with no commercial applications yet available. This delay may stem from their recent development compared to wild-type phages and the absence of comprehensive risk assessment criteria. Currently, clearly defined criteria for risk classification of bacteriophages and their applications are limited, and risk assessment is primarily done on a case-by-case basis. There is a critical need for effective testing methodologies to evaluate genetic alterations and their implications. Moreover, the lack of regulatory frameworks for modified phage products poses challenges for their adoption. To address these issues, tailored regulatory guidelines and collaboration among regulatory bodies, industry, and researchers are essential. -
From 11:00 to 12:20
Session 2 Poster pitches
- Advancing Biosafety from Campus to Nation: NUS's Comprehensive Training and National Harmonisation Efforts
Cheh Peng LIm - Guideline validation and verification of inactivation
Paul Odinot - Containment measures for the application of biological control agents in greenhouses with GM plants in the Netherlands
Iris Riemersma - Biosafety practices in the autopsy facilities
Susanne Sissonen - Evaluating Biological Risks in Biomedical laboratories of Primary Health Care Centers
Dionysios Vourtsis - Collaborative Biological Risk Assessment: A Diversified and Inclusive Team-Based Approach to Risk Mitigation
Rachel Gamble - Who writes the safety datasheets for Advanced Therapeutic Medicinal Products ?
Arthur Kroon - Downscaling of containment requirements for work with alphavirus replicons: precautionary measures for the formation of infectious Virus-Like Vesicles
Clara Posthuma - Bridging the Biosafety Knowledge Gap through Essential BSL-3 Training
Haley DeMers - The Iceberg of Incident Reporting
Adrian Worrall
- Advancing Biosafety from Campus to Nation: NUS's Comprehensive Training and National Harmonisation Efforts
-
From 13:30 to 14:00
Are You Overdesigning Your Waste Treatment Systems?
A discussion about equipment for high containment application
Gary Schmidt, Products and Process Technology Manager, PRI-Bio
Waste treatment systems serve to protect both personnel and the environment from biological hazards in the laboratories or facilities. It can be easy to add “bells and whistles” in an attempt to enhance the design, but experience has proven that, in many instances, the “less is more” concept provides the most robust solution. In this talk we offer several examples of “features or design elements” that can have a negative impact on Thermal Effluent Decontamination Systems, however, these concepts apply to equipment in general. This discussion is targeted at those who use, design and specify waste treatment systems in containment facilities.
-
From 13:30 to 14:00
Do biowaste decontamination systems need to be to sanitary design?
Suncombe has delivered a number of significant biowaste decontamination projects over the years. There will be detailed discussions around how mechanical designs have been developed for plants installed 10-15 years ago through to current projects. How has the plants performed over the years and what have we learnt? What are the greatest challenges and how are they overcome? What is the optimum automation philosophy and how is it implemented?
We hope that the presentation will stimulate lots of questions and that we jointly can answer the question: Do biowaste decontamination systems need to be to sanitary design?
-
From 14:00 to 14:30
Overcrowding in a Biosafety Cabinet
Commercial presentation Baker
presenter: Diko Strietman, Managing director Baker Europe
-
From 14:00 to 14:30
Commercial presentation delox -Solid hydrogen peroxide for safe aerial transportation and compact bio-decontamination equipment
Hydrogen peroxide (H₂O₂) is widely used for bio-decontamination due to its high efficacy and residue-free decomposition into water and oxygen. H₂O₂-based bio-decontamination technologies fall into two main categories based on their physical processes: vaporization and nebulization. In vaporization, H₂O₂ vapor is generated using a complex flash-vaporization method, which is effective but expensive. In contrast,nebulization consists of spraying larger H₂O₂ particles, which is more affordable, but less effective.Here, we present DeloxHP, a solid formulation of H₂O₂, in which H₂O₂ is stored within the nanopores of a silica-based material. Unlike vaporization and nebulization, where H₂O₂ is released from an aqueoussolution (liquid state), DeloxHP releases H₂O₂ from an adsorbed state. This means that the H₂O₂ molecules are stored in a solid matrix in a more dispersed form than in a liquid solution. As a result, DeloxHP enables the controlled release of true H₂O₂ vapor using a much simpler technology than flash vaporization, while maintaining the same high bio-decontamination efficacy (eliminating 99.9999% of microorganisms).This innovation allows vaporization devices to be downscaled to fit various application constraints.Vaporization systems using DeloxHP are particularly advantageous in environments where portability isrequired for moving bio-decontamination units, or where space is limited, requiring a compact system.These systems are also highly robust and capable of operating in harsh environments without sensitive components. Additionally, DeloxHP ensures the safe transportation of concentrated H₂O₂, as it is notclassified as a hazardous material and is not subject to transport restrictions according to UN test O.1.In conclusion, DeloxHP enables the development of automatic bio-decontamination systems that are highly efficient, robust, portable, and affordable, democratizing access to state-of-the-art bio-decontamination technology. -
From 14:30 to 15:00
Commercial presentation Actini - What is a Safety device dedicated to the Biosafety and how is evaluated the reliability of each type of device
In this session we will remind what is a Safety device dedicated to the Biosafety and how is evaluated the reliability of each type of device. -
From 14:30 to 15:00
Containment in the Age of High Potency Compounds: Innovations for Research and Pharmaceutical Applications
Presenters: Leticia Lema and Roberto Buzzi, from Telstar
-
From 15:00 to 16:00
Chris Collins lecture - Biosafety and Biosecurity in the Age of Artificial Intelligence - Piers Millet
Piers MIllett, Executive Director,
International Biosecurity and Biosafety Initiative for ScienceArtificial intelligence is changing our world. Each week brings new revelations on technical advances as well as debate over the implications of the technology for our societies. Whether it proves to be out undoing or our savior, we are already seeing artificial intelligence prompting major changes in biology. It provides powerful new approaches to unpick the complexity of biology, furthering our fundamental understandings, and enables new tools to help solve local and global challenges.
Three different but interconnected applications of artificial intelligence in biology have already been identified: large language models (like DeepSeek) open the door to more ready access to information and protocols which could help drive research and development; design tools (like AlphaFold) are bringing us ever closer to being able to design for specific biological function; and integration of artificial intelligence into hardware is enabling self-driving laboratories (like Genesis).
With these exciting opportunities, comes risks of accidental or deliberate harm. These tools open the door to more people, in more places, being able to access the incredible power of biology, including those that would use it irresponsibly. Artificial intelligence driven advances could challenge existing biosafety and biosecurity rules, procedures, and practices. It is increasingly important that we review, revise, and reinforce the way we safeguard the digital to biological interface where in silico research becomes in vitro artifact. In the European context, this must include:
(1) better understanding of critical capabilities, such as where synthetic nucleic acids are made or supplied in, and the rules that govern them;
(2) effective and efficient tools to support decision-making around who has access to what dual-use material;
(3) adaptive, risk-based international rules, developed collaboratively and inclusively to fit national needs and contexts; and
(4) policy engagement to explain why national and regional rules are necessary, and to highlight the opportunities offered by acting now and the risks inherent in ignoring the implications of artificial intelligence for biological research and development. -
From 16:30 to 16:50
Session 3 Sustainability Biosafety - Sustainable labs through the lens of bottom-up initiative raised change – without restriction?! - Jan Heidelberger
Jan Heidelberg, Scientific Coordinator, Max Planck School Matter to Life, Germany
The operation of a modern laboratory is associated with the use of large quantities of diverse resources, for example, consumables, energy or water. These can already be reduced and minimized in a variety of ways or replaced by alternatives. This means not only adapting one's own working methods, but also making better use of resources and integration of all stakeholders.The goal must be to reduce the unnecessary, optimize the necessary and initiate a change in thinking in order to achieve a closed life cycle. However, a sustainable laboratory and the choice of measures also mean consistent or increasing quality and no contradiction to safety in the laboratory. What might the path towards a sustainable laboratory look like and what difficulties might arise? What does this mean for me in the laboratory, but also for my institute or facility? -
From 16:50 to 17:10
Session 3 Sustainability Biosafety - The sustainable way to operate a large BSL2 facility for experiments with livestock animals - Roberto Plasenzotti
Roberto Plasenzotti, SAN Group, AustriaThe SAN Group wants to be NetZero by 2027, therefore even the new animal experimental laboratory which was completed in 2023 is committed to this goal. Many measures were taken to be energy independent although running a large-scale livestock animal experimental lab.
All the Critical Control points needed to run a BSL2 experiment for livestock animals like eg. pigs are assessed even under the perspective of energy reduction.
All the energy is generated via photovoltaic systems or via our own biogas system which is also using the pig manure produced during the various experiments.
The new plant uses a large scale battery system as well as deep drilling for heat generation. The single rooms are controlled individually for heating, cooling and air exchange.
-
From 17:10 to 17:30
Session 3 Sustainability Biosafety - Biosafety and Sustainability : Two sides of the same coin or not? - Partha Krisnan
Partha Krishnan, Workplace Health and Safety Change Agent | Lab Sustainability Catalyst, Sanofi, United States
This presentation will focus on areas where sustainability and biosafety go together like PPE made from compostable material or use of centrifuge tubes made from plant oils. The presentation will also talk about use of glass which is frowned upon in Biosafety but makes sense for sustainability for reuse. The presenter will make number of case studies illustrating how these two subjects can be treated in the lab. -
From 9:00 to 9:30
Session 4 Biosafety behaviour and Bio-ethics - How to support lifelong learning of biosafety professionals in a world of change? - Simon Beausaert
Simon Beausaert, professor Learning and Development in Organisations, Maastricht University, The Netherlands
We all live and work in a rapidly changing society. Biosafety professionals also operate in this complex environment where rules and procedures change, new viruses emerge and AI makes its appearance. In order to remain employable to face these dynamics, bio-safety organizations realize the importance of having competent, flexible employees. As a result, many organizations are putting lifelong learning high on the strategic agenda. Lifelong learning refers to training on the one hand and informal learning on the other. Training and informal learning are only possible when the organization supports learning. The question remains: How can an organization best support lifelong development?
-
From 9:30 to 9:50
Session 4 Biosafety behaviour and Bio-ethics - Enhancing Biosafety and Biosecurity in High-Containment Laboratories: A Psychological Approach to Training Laboratory Personnel - Balazs Somogyi
Balazs Somogyi, University of Pécs, National Laboratory of Virology, Hungary
High-containment laboratories (HCLs), including BSL-3 and BSL-4 facilities, face significant biosafety and biosecurity challenges, particularly in managing human and procedural factors. This systematic review examines the psychological and organizational elements influencing safety and biosecurity outcomes. Key human factors include stress, cognitive overload, fatigue, and behavioral compliance, while procedural challenges encompass inconsistent training protocols, non-standardized local guidelines, and resource limitations. A comprehensive systematic search of five databases identified 57 studies meeting inclusion criteria, providing insights into the interplay between psychological factors and laboratory practices.The findings reveal that stress and cognitive load are major barriers to effective training and compliance with safety protocols. Behavioral compliance improves following training; however, systemic issues such as fatigue, resource constraints, and fragmented regulatory frameworks hinder sustainable adherence. Leadership practices prioritizing empathy, communication, and collaboration are critical in fostering a supportive safety culture. Additionally, scenario-based training, task simplification, and fatigue management emerged as promising strategies for improving safety outcomes.To address these challenges, we propose a modular, competency-based training framework that integrates psychological and organizational strategies. Scenario-based training and advanced monitoring technologies are recommended to enhance risk perception and adherence to protocols. These interventions, coupled with leadership engagement and improved resource allocation, can significantly improve biosafety and biosecurity outcomes in HCLs. Implementing these strategies requires a holistic approach that balances human and procedural factors, ensuring long-term safety and sustainability in these high-risk environments. -
From 9:50 to 10:10
Session 4 Biosafety behaviour and Bio-ethics - Marsh v Baxter Ten Years On: Learning from the Regulation of the Coexistence of GM and Non-GM Crops in Australia - Michael Ivanov
Michael Ivanov, The University of Adelaide, Australia
Ten years ago, Marsh, an organic farmer from Western Australia found swathes of genetically modified canola on his paddock after they had blown over from his neighbour’s farm. Consequently, Marsh lost his organic certification and experienced financial loss. He unsuccessfully sought compensation for having his organic crops ‘contaminated’ by the presence of genetically modified material on his farm. The case was called Marsh v Baxter and it was the first of its kind in Australia.Since the Supreme Court of Western Australia delivered its judgement in 2015, there has been an ongoing concern as to how genetically modified crops can coexist with conventional or organic crops. This presentation provides an overview of the case and considers the legal and regulatory impact it has had across Australia over the past ten years. Drawing on laws, codes of conduct and farming standards, this presentation examines what has changed and what might change in the future based on Australia’s increasing development and cultivation of genetically modified and genome edited crops. In hearing about the regulatory responses in Australia, other jurisdictions can learn from Australia’s lessons and regulate the coexistence of different crop types – genetically modified or otherwise – more effectively and in an ethical manner which upholds the social and economic interests of all relevant stakeholders. -
From 10:10 to 10:30
Session 4 Biosafety behaviour and Bio-ethics - Good Friday or Black Friday? - Marcel van Bergen
Marcel van Bergen, BioRiskManager, Radboudumc and Radboud University, The Netherlands
Incident reporting is a vital aspect of biorisk management, essential for controlling and preventing future incidents. Over the past decade, we have identified a pattern indicating an increase in incident reporting towards the end of the week, known as the "Friday effect." This study investigates the validity of this pattern.Our research aims to determine:- whether more incidents occur towards the end of the week,
- if there is a discrepancy between the number of incidents occurring and those reported at the end of the week, and
- whether this pattern is consistent across all risk types or specific to certain types, such as laboratory biorisks.
We conducted an oral inventory and a systematic literature review, followed by a comprehensive analysis of incident reports over a five-year period (2020-2024). This analysis encompassed data from various levels, including organizations, departments, laboratories, patients, and employees.In our presentation, we will share the analyzed data from the past five years, highlighting the role of weekday timing in incident reporting and the possible presence of the "Friday effect." We will also explore potential causes of this phenomenon and discuss whether Fridays should be considered beneficial or problematic in the context of incident reporting. -
From 11:00 to 11:40
Break-out 1.1 - Transport of biological materials - Mario Vaerewijck and René Custers
Maro Vaerewijck, Biosafety coordinator, UGent, Belgium
René Custers, Regulatory & Responsible Research manager, VIB, BelgiumThe break-out session will be on the import, export and transport of biological materials, the different types of regulations triggered by it, and its consequences for the shipments in terms of the way they are packed, labelled and documented.
-
From 11:00 to 11:40
Break-out 2.1 - Challenges in large scale production sites (biosafety in GMP area) - Jolanda Van Beusichem - Van Der Laan, Frank Vervoort, Kelly ann Bradley
Jolanda Van Beusichem - Van Der Laan, Scientist QC New Product Introduction, The Janssen Pharmaceutical, The Netherland
Frank Vervoort, Upstream Lead Pollux, Janssen Vaccines & Prevention, The NetherlandsCleanrooms for large-scale production must meet both GMP and biosafety requirements, but how do these priorities align—or conflict? This 40-minute interactive session provides an introduction to key cleanroom challenges, focusing on:
- Gowning & material route: Managing personnel & material flow and gowning procedures to maintain containment.
- Spill Management: Responding to major and minor spills while balancing biosafety and operational continuity.
- Pressure cascades: creating differential pressures to maintain both containment and cleanroom compliance
Through practical scenarios, participants will gain a clearer understanding of cleanroom design considerations and operational constraints, fostering awareness of the interplay between biosafety and GMP compliance in controlled environments.
-
From 11:00 to 11:40
Break-out 3.1 - Biosecurity Escape Room - Iris Vennis, Mirjam Schaap, Mirjam Schuijff, Ngoc Hoa Chung
Iris Vennis, Global Health Security Scientist, RIVM, The Netherlands
Mirjam Schaap, Scientist, RIVM, The Netherlands
Mirjam Schuijff, Policy Officer, RIVM, The Netherlands
Ngoc Hoa Chung, Policy Officer , RIVM, The NetherlandsDo you have what it takes to escape the biosecurity escape room? Do you want to explore biosecurity in a completely new way? Then join us in our fictive lab to learn about the biosecurity pillars while you solve the mystery!
Working with high-risk pathogens, high-risk material, and sensitive material entails various risks. Employees should be aware of these risks and the corresponding control measures that can be taken. This enables employees to help identify risks, remain vigilant and adhere to the rules. Employees with biosecurity awareness can assess potential dual-use risks, recognise abnormal situations and hold colleagues accountable for their behaviour.
There are many ways to raise biosecurity awareness. The approach can vary per target group in the organisation. For employees working in a laboratory, biosecurity should be included in the induction programme for new employees, and periodic attention should be paid to the security aspects of lab work. Awareness is important for all types of lab work and for all employees in a laboratory, not only for those working with high-risk material.
In the biosecurity escape room you will experience an interactive approach to increase your biosecurity awareness!
-
From 11:00 to 11:40
Break-out 4.1 - Working with plant pathogens in contained facilities - Pieter Boonen and Barbara De Coninck
Pieter Boonen, Global Biosafety and Stewardship manager, BASF Vegetable Seeds, The Netherlands
Barbara De Coninck, Associate Professor, KU Leuven division Crop Biotechnics, BelgiumRegulatory frameworks governing the use of plant pathogens in research facilities, including laboratories, growth rooms, and greenhouses, vary significantly between countries. These regulations cover aspects such as the handling of plant pathogens, quarantine organisms, and the exposure of genetically modified plants to such pathogens. While some plant pathogens are strictly regulated under contained use legislation across all EU member states, others may fall under different national frameworks. For example, in Belgium, all plant pathogens are subject to contained use regulations, with additional requirements under plant health legislation for quarantine organisms. In contrast, the Netherlands applies plant health legislation only to quarantine and quarantine-equivalent plant pathogens but may impose specific requirements on laboratories handling plant pathogens.
During this break-out session, we will first provide insights into how an industrial company in the Netherlands and an academic institute in Belgium handle plant pathogens in compliance with their respective regulatory frameworks. We will explore how these regulations shape the execution of experiments in practice, highlighting key differences and challenges. Following this, we aim to engage participants in a discussion on best practices, the practical implications of varying regulations across EU member states, and potential strategies for navigating inconsistencies in regulatory requirements.
This session aims to foster dialogue among researchers, regulatory experts, and industry representatives to identify challenges and potential solutions for harmonizing research practices across different regulatory landscapes.
-
From 11:00 to 11:40
Break-out 5.1 - Lab Design and Workflow – Getting It Right Every Time! - Aurel Tamburri and Ryan Gregory
Aurel Tamburri, Senior Scientist, Laboratory Operations, Merrick & Co, Canada
Ryan Gregory, Senior Engineer, Merrick, Canada
Uwe Müller Doblies, AustriaObjectives:Understand the critical role of effective laboratory design.Integrate design and workflow considerations to support modernization, automation, or renovation projects.Assemble and lead a project team to execute lab builds or renovations that prioritize efficiency, minimize risks, and meet stakeholder needs.Whether planning a new laboratory facility, renovating an existing space, modernizing diagnostic services, or preparing for future adaptability, a well-structured approach is essential to save time, money, and effort. This presentation provides a comprehensive framework for designing and managing laboratory facilities that are resilient, efficient, and future-ready.Participants will gain insights into integrating scientific, safety, and operational needs into design strategies, optimizing workflows, and benchmarking against industry best practices. The session delves into the laboratory design process, offering guidance on planning for technological advancements, ensuring regulatory compliance, and managing transitions effectively.Key topics include:- Laboratory design process: Developing facility layouts that balance operational efficiency, flexibility, and compliance.
- Biorisk and quality management: Enhancing safety and maintaining operational excellence.
- Workflow optimization: Aligning lab processes with design to improve productivity and adaptability.
- Long-term continuity planning: Preparing for advancements in science, technology, and regulations.
- Stakeholder engagement and transparency: Building trust and collaboration with regulators, users, and project teams.
By the end of this session, attendees will be equipped with the knowledge to navigate the laboratory design process and create environments that adapt seamlessly to programmatic and external changes, ensuring sustained operational success while mitigating risks and inefficiencies. -
From 11:00 to 11:40
Break-out 6.1 - Surface sampling and surface disinfection methodologies for the laboratory and beyond
Allan Bennett, Bennett Biosafety, United Kingdom
Ingrid Vande Velde, Johnson & Johnson, Belgium -
From 11:50 to 12:30
Break-out 1.2 - Transport of biological materials - Mario Vaerewijck and René Custers
Maro Vaerewijck, Biosafety coordinator, UGent, Belgium
René Custers, Regulatory & Responsible Research manager, VIB, BelgiumThe break-out session will be on the import, export and transport of biological materials, the different types of regulations triggered by it, and its consequences for the shipments in terms of the way they are packed, labelled and documented.
-
From 11:50 to 12:30
Break-out 2.2 - Challenges in large scale production sites (biosafety in GMP area) - Jolanda Van Beusichem - Van Der Laan, Frank Vervoort, Kelly ann Bradley
Jolanda Van Beusichem - Van Der Laan, Scientist QC New Product Introduction, The Janssen Pharmaceutical, The Netherland
Frank Vervoort, Upstream Lead Pollux, Janssen Vaccines & Prevention, The NetherlandsCleanrooms for large-scale production must meet both GMP and biosafety requirements, but how do these priorities align—or conflict? This 40-minute interactive session provides an introduction to key cleanroom challenges, focusing on:
- Gowning & material route: Managing personnel & material flow and gowning procedures to maintain containment.
- Spill Management: Responding to major and minor spills while balancing biosafety and operational continuity.
- Pressure cascades: creating differential pressures to maintain both containment and cleanroom compliance
Through practical scenarios, participants will gain a clearer understanding of cleanroom design considerations and operational constraints, fostering awareness of the interplay between biosafety and GMP compliance in controlled environments.
-
From 11:50 to 12:30
Break-out 3.2 - Biosecurity Escape Room - Iris Vennis, Mirjam Schaap, Mirjam Schuijff, Ngoc Hoa Chung
Iris Vennis, Global Health Security Scientist, RIVM, The Netherlands
Mirjam Schaap, Scientist, RIVM, The Netherlands
Mirjam Schuijff, Policy Officer, RIVM, The Netherlands
Ngoc Hoa Chung, Policy Officer , RIVM, The NetherlandsDo you have what it takes to escape the biosecurity escape room? Do you want to explore biosecurity in a completely new way? Then join us in our fictive lab to learn about the biosecurity pillars while you solve the mystery!
Working with high-risk pathogens, high-risk material, and sensitive material entails various risks. Employees should be aware of these risks and the corresponding control measures that can be taken. This enables employees to help identify risks, remain vigilant and adhere to the rules. Employees with biosecurity awareness can assess potential dual-use risks, recognise abnormal situations and hold colleagues accountable for their behaviour.
There are many ways to raise biosecurity awareness. The approach can vary per target group in the organisation. For employees working in a laboratory, biosecurity should be included in the induction programme for new employees, and periodic attention should be paid to the security aspects of lab work. Awareness is important for all types of lab work and for all employees in a laboratory, not only for those working with high-risk material.
In the biosecurity escape room you will experience an interactive approach to increase your biosecurity awareness!
-
From 11:50 to 12:30
Break-out 4.2 - Working with plant pathogens in contained facilities - Pieter Boonen and Barbara De Coninck
Pieter Boonen, Global Biosafety and Stewardship manager, BASF Vegetable Seeds, The Netherlands
Barbara De Coninck, Associate Professor, KU Leuven division Crop Biotechnics, BelgiumRegulatory frameworks governing the use of plant pathogens in research facilities, including laboratories, growth rooms, and greenhouses, vary significantly between countries. These regulations cover aspects such as the handling of plant pathogens, quarantine organisms, and the exposure of genetically modified plants to such pathogens. While some plant pathogens are strictly regulated under contained use legislation across all EU member states, others may fall under different national frameworks. For example, in Belgium, all plant pathogens are subject to contained use regulations, with additional requirements under plant health legislation for quarantine organisms. In contrast, the Netherlands applies plant health legislation only to quarantine and quarantine-equivalent plant pathogens but may impose specific requirements on laboratories handling plant pathogens.
During this break-out session, we will first provide insights into how an industrial company in the Netherlands and an academic institute in Belgium handle plant pathogens in compliance with their respective regulatory frameworks. We will explore how these regulations shape the execution of experiments in practice, highlighting key differences and challenges. Following this, we aim to engage participants in a discussion on best practices, the practical implications of varying regulations across EU member states, and potential strategies for navigating inconsistencies in regulatory requirements.
This session aims to foster dialogue among researchers, regulatory experts, and industry representatives to identify challenges and potential solutions for harmonizing research practices across different regulatory landscapes.
-
From 11:50 to 12:30
Break-out 5.2 - Lab Design and Workflow – Getting It Right Every Time! - Aurel Tamburri and Ryan Gregory
Aurel Tamburri, Senior Scientist, Laboratory Operations, Merrick & Co, Canada
Ryan Gregory, Senior Engineer, Merrick, Canada
Uwe Müller Doblies, AustriaObjectives:Understand the critical role of effective laboratory design.Integrate design and workflow considerations to support modernization, automation, or renovation projects.Assemble and lead a project team to execute lab builds or renovations that prioritize efficiency, minimize risks, and meet stakeholder needs.Whether planning a new laboratory facility, renovating an existing space, modernizing diagnostic services, or preparing for future adaptability, a well-structured approach is essential to save time, money, and effort. This presentation provides a comprehensive framework for designing and managing laboratory facilities that are resilient, efficient, and future-ready.Participants will gain insights into integrating scientific, safety, and operational needs into design strategies, optimizing workflows, and benchmarking against industry best practices. The session delves into the laboratory design process, offering guidance on planning for technological advancements, ensuring regulatory compliance, and managing transitions effectively.Key topics include:- Laboratory design process: Developing facility layouts that balance operational efficiency, flexibility, and compliance.
- Biorisk and quality management: Enhancing safety and maintaining operational excellence.
- Workflow optimization: Aligning lab processes with design to improve productivity and adaptability.
- Long-term continuity planning: Preparing for advancements in science, technology, and regulations.
- Stakeholder engagement and transparency: Building trust and collaboration with regulators, users, and project teams.
By the end of this session, attendees will be equipped with the knowledge to navigate the laboratory design process and create environments that adapt seamlessly to programmatic and external changes, ensuring sustained operational success while mitigating risks and inefficiencies. -
From 11:50 to 12:30
Break-out 6.2 - Surface sampling and surface disinfection methodologies for the laboratory and beyond
Allan Bennett, Bennett Biosafety, United Kingdom
Ingrid Vande Velde, Johnson & Johnson, Belgium -
From 13:30 to 13:50
Session 5 Developments in Applied Biosafety - Turning Biohazards into Ashes: keeping the path to incineration safe. - Patrick Rüdelsheim
Patrick Rüdelsheim, Director, Chief Regulatory Officer, Perseus a 3Bio company
Incineration of biological material is the gold standard for eliminating risks of exposure and spread. By centralizing these processes in specialized facilities, we can achieve the highest quality and environmental standards. But for those producing biohazardous waste, the journey seems to end when they close the bin and see it picked up by the transport company. In reality, this waste embarks on an adventurous journey before it faces total inactivation.Commissioned by the Ministry of Infrastructure and Water Management in the Netherlands, our study maps this fascinating process from collection to the disposal of ashes. We evaluate potential risks and clarify the safety measures that ensure safe handling at the incineration site. One major challenge is the lack of detailed information on the waste material, which reduces risk assessment to a generic exercise and leads to possibly oversized safeguards. To ensure proper containment until the final stage, only incineration facilities equipped to handle hazardous medical waste can offer the necessary conditions.This talk will dive into the key challenges faced by incineration facilities and highlight the crucial role of waste producers. The incineration facility has established specific guidelines and acceptance criteria, communicated to waste producers through collectors. These guidelines ensure that all parties operate consistently and safely. Waste producers bear significant responsibility and, by adhering to these guidelines, make a vital contribution to preventing incidents. -
From 13:50 to 14:10
Session 5 Developments in Applied Biosafety - Comprehensive Approach to Large Scale High-Containment Laboratory Decontamination - Aurel Tamburri and Ryan Gregroy
Aurel Tamburri, Senior Scientist, Laboratory Operations, Merrick & Co, Canada
Ryan Gregory, Merrick & Co, Canada
Objectives:
Understand the challenges and complexities of decontaminating high-containment laboratory facilities.Evaluate decontamination methods based on key criteria such as efficacy, material compatibility, and environmental impact.Learn strategies to meet regulatory compliance and ensure successful validation.Explore approaches for collaborative planning and phased execution to minimize risks and maximize efficiency.This presentation offers a detailed overview of a large-scale decontamination project for a high-containment laboratory facility, encompassing over 200,000 square feet of containment zones and support spaces. Conducted as part of a facility shutdown and relocation, the project illustrates the complexities of decommissioning and decontaminating laboratories handling regulated biological agents.Key topics include:- Facility Background: Overview of the laboratory’s multi-building structure and containment areas.
- Decontamination Methods and Selection Process: Evaluation of multiple approaches based on efficacy, material compatibility, environmental impact, and safety considerations.
- Regulatory Compliance and Validation: Strategies for meeting stringent biosafety and environmental standards, ensuring full regulatory clearance.
- Environmental Sampling and Setup: Pre-decontamination assessments, use of indicators for validation, and phased isolation.
- Execution and Outcomes: Insights into application techniques, validation processes, and post-decontamination clearance to support reuse or decommissioning.
The presentation provides lessons learned, emphasizing the value of collaborative planning, stakeholder engagement, and phased execution to achieve successful decontamination while maintaining safety and efficiency. Attendees will gain actionable strategies for managing similar projects in high-containment laboratory environments. -
From 14:10 to 14:30
Session 5 Developments in Applied Biosafety - Development of a New Inhalation Model for Occupational Hygiene: Assessing Exposure to Bioaerosols - Carlota Alejandre Colomo
Carlota Alejandre Colomo, Health and Safety - Occupational hygienist, Cosanta B.V. - Stoffenmanager, The Netherlands
Occupational risk assessments for biological agents have traditionally received less attention compared to chemical hazards, despite their significant health implications. The COVID-19 pandemic underscored the critical need to address risks associated with biological agents in workplace environments. However, existing tools for hazard inventory, risk assessment, and control implementation for biological agents remain limited.Over recent decades, various qualitative tools have been developed to assess risks from biological agents, including the INSST’s Simplified Evaluation (Spain), INVASSAT’s Biogaval-Neo (Spain), IRSST’s Bioaerosol Tool (Canada), and NKAL’s RIE Method (Netherlands). These tools vary in scope, methodology, and parameters, prompting a detailed comparison to identify their strengths, limitations, and areas for improvement. Key parameters have been proposed to enhance these tools, serving as the foundation for the development of a novel qualitative risk assessment model.A new semi-quantitative exposure assessment model has been designed, focusing on bioaerosol inhalation and utilizing a source-receptor conceptual framework. Scores for each parameter were derived from literature reviews and expert judgment. The model has been tested across more than 150 real workplace scenarios, encompassing sectors such as waste disposal, wastewater treatment, healthcare, food production, forestry, and laboratories. Its structured approach facilitates distinguishing exposure levels and assessing the effectiveness of control measures. The proposed advancements aim to standardize risk assessments and better protect workers from biological hazards. -
From 14:30 to 14:50
Session 5 Developments in Applied Biosafety - Containment or Catastrophe: Embracing Process Safety in Biorisk Management - Jaspreet Chana
Jaspreet Chana, Environmental Resources Management, United Kingdom
In the wake of the COVID-19 outbreak and within the rapidly evolving fields of research and biotechnology, managing biological risks has never been more crucial for the safety of personnel and the environment. This presentation explores the critical need to integrate process safety principles into biorisk management to prevent accidental releases and major accidents.Through case studies and incidents, we will highlight the consequences of inadequate containment and demonstrate how adopting industry standards and best practices from high-hazard industries can help identify potential failures and design robust controls.This holistic approach not only enhances biosafety but also fosters a culture of continuous improvement and resilience against emerging biological threats. Key topics include hazard identification, risk assessment, fail-safe system design, and the importance of a proactive safety culture and continuous monitoring.